title: Mobilization/transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's lymphoma with marrow involvement.
abstract: Thirty-five aggressive non-Hodgkin's lymphomas (NHL) with marrow involvement received high-dose cyclophosphamide (7 g/m2) and G-CSF in order to collect peripheral blood progenitor cells (PBPC). Fourteen patients were in partial remission, 16 patients were in relapse ('sensitive', 12; 'resistant', 4) and five patients were refractory to conventional treatment. A good yield of PBPC was obtained in 30 patients, while a low number of CD34+ cells and of CFU-GM was seen in two cases. Two patients entered progression and one patient died. Thirty patients underwent PBPC autografting. Twenty-nine out of 35 (83%) patients entered complete remission (CR). Two patients died in CR of infection following marrow aplasia 3 and 6 months after autografting. At 3 years the probability of survival and disease-free survival (DFS) are 62 and 51%, respectively.
authors.affiliation: Department of Hematology, Ospedale S Martino, Genova, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Santini
authors.forename: A M
authors.initials: AM
authors.lastname: Congiu
authors.forename: S
authors.initials: S
authors.lastname: Nati
authors.forename: D
authors.initials: D
authors.lastname: Pierluigi
authors.forename: M
authors.initials: M
authors.lastname: Spriano
authors.forename: T
authors.initials: T
authors.lastname: Chisesi
authors.forename: E
authors.initials: E
authors.lastname: Rossi
authors.forename: R
authors.initials: R
authors.lastname: Vimercati
authors.forename: M R
authors.initials: MR
authors.lastname: Sertoli
authors.forename: O
authors.initials: O
authors.lastname: Figari
authors.forename: M
authors.initials: M
authors.lastname: Gobbi
authors.forename: G
authors.initials: G
authors.lastname: Piaggio
authors.forename: F
authors.initials: F
authors.lastname: Vassallo
authors.forename: F
authors.initials: F
authors.lastname: Benvenuto
authors.forename: M
authors.initials: M
authors.lastname: Soracco
authors.forename: M
authors.initials: M
authors.lastname: Miglino
authors.forename: R
authors.initials: R
authors.lastname: Bruni
authors.forename: J L
authors.initials: JL
authors.lastname: Ravetti
authors.forename: M
authors.initials: M
authors.lastname: Truini
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007937:Leukapheresis; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D016019:Survival Analysis
chemical_list: D018906:Antineoplastic Agents, Alkylating; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide